Search for: All records

OBJECTIVE: Rapamycin prolongs reproductive lifespan in mice by halting primordial follicle activation. The impact of rapamycin on the preantral follicle pool and senescence markers during ovarian aging in macaques was evaluated. MATERIALS AND METHODS: One ovary was removed from young (n=2, 6–9 yr) and old (n=2, 17–21 yr) adult female rhesus macaques during a normal menstrual cycle (pre-treatment). The remaining ovary was obtained after animals were treated with rapamycin (bid, IM, 0.02mg/kg) for 10 months. Ovaries were fixed and serially sectioned for follicle counting (each 10th section, 15-39 sections/ovary). Immunohistochemical analyses were performed for anti-Mullerian hormone (AMH) and cellular senescence markers p16, p53, and p21 (1 slide/ovary). Qualitative comparisons were made due to the small sample size. RESULTS: The primordial follicle pool was decreased in young (3,939 pre-treatment vs. 2,219 post-treatment), but similar in old (555 pre- vs. 574 post-treatment) females after rapamycin. The number of transitional primordial follicles was greater before rapamycin than after in both young (14,920 vs. 4,924) and old (1,915 vs. 1,311) females. The number of primary follicles before (2,617) rapamycin was greater than after (560) in young and old females (518 pre- vs. 428 post-treatment). A similar proportion of follicles positive for p16 was seen before and after rapamycin in both young and old females. Similar findings were also observed for AMH, except there are fewer positive follicles in the rapamycin-treated older group. The proportion of follicles staining positive for both p53 and p21 was increased in both young and old monkeys after treatment. CONCLUSIONS: Rapamycin had no impact on the primordial and primary follicle pools in old female macaques while unexpectedly decreasing both pools in young females. While the number of p16-positive follicles was unaffected by rapamycin treatment, the number of p53 and p21-positive follicles was increased by treatment in both age cohorts. IMPACT STATEMENT: At the dose and treatment interval used, rapamycin does not appear to suppress follicular activation and has mixed effects on senescence markers in aging nonhuman primate ovaries. 

Abstract In women, excess androgen causes polycystic ovary syndrome (PCOS), a common fertility disorder with comorbid metabolic dysfunctions including diabetes, obesity, and nonalcoholic fatty liver disease. Using a PCOS mouse model, this study shows that chronic high androgen levels cause hepatic steatosis while hepatocyte-specific androgen receptor (AR)-knockout rescues this phenotype. Moreover, through RNA-sequencing and metabolomic studies, we have identified key metabolic genes and pathways affected by hyperandrogenism. Our studies reveal that a large number of metabolic genes are directly regulated by androgens through AR binding to androgen response element sequences on the promoter region of these genes. Interestingly, a number of circadian genes are also differentially regulated by androgens. In vivo and in vitro studies using a circadian reporter [Period2::Luciferase (Per2::LUC)] mouse model demonstrate that androgens can directly disrupt the hepatic timing system, which is a key regulator of liver metabolism. Consequently, studies show that androgens decrease H3K27me3, a gene silencing mark on the promoter of core clock genes, by inhibiting the expression of histone methyltransferase, Ezh2, while inducing the expression of the histone demethylase, JMJD3, which is responsible for adding and removing the H3K27me3 mark, respectively. Finally, we report that under hyperandrogenic conditions, some of the same circadian/metabolic genes that are upregulated in the mouse liver are also elevated in nonhuman primate livers. In summary, these studies not only provide an overall understanding of how hyperandrogenism associated with PCOS affects liver gene expression and metabolism but also offer insight into the underlying mechanisms leading to hepatic steatosis in PCOS.